Madrigal Pharmaceuticals, Inc.
MDGL Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$440.33
KIRA · Stoqly’s AI analyst, in plain words
- Madrigal Pharmaceuticals, Inc. had $958M of revenue in fiscal 2025, up 432.1% on the year before.
- Its operating margin was −31.3%, up 245.1 pts: of every 100 in sales, about −31 is left after running the business.
- Madrigal Pharmaceuticals, Inc. lost $288M in fiscal 2025.
- Free cash flow was −$190M in fiscal 2025, −19.8% of revenue.
- Madrigal Pharmaceuticals, Inc. has $644M more cash than debt.
Market cap
$12.8B
P/E
—
Revenue
$958M
Net income
−$288M
Free cash flow
−$190M
Operating margin
−31.3%
Madrigal Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+432.1%
Yes. Sales grew 432.1% last year.
Does it make a profit?
−30.1%
No. It lost money last year.
Does profit turn into cash?
−19.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Madrigal Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- MADRIGAL PHARMACEUTICALS, INC.
- CIK
- 0001157601
Madrigal Pharmaceuticals, Inc. · MDGL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $180M | $958M |
| Revenue growth | — | — | — | — | 432.1% |
| Gross margin | — | — | — | 96.5% | — |
| Operating margin | — | — | — | −276.4% | −31.3% |
| Net income | −$242M | −$295M | −$374M | −$466M | −$288M |
| Net margin | — | — | — | −258.6% | −30.1% |
| Diluted EPS | −$14.63 | −$17.23 | −$17.33 | −$17.31 | −$10.15 |
| Cash | |||||
| Cash from operations | −$184M | −$225M | −$324M | −$456M | −$190M |
| Capital expenditure | $0.2M | $0.2M | $1.5M | $1.5M | $0.5M |
| Free cash flow | −$184M | −$225M | −$326M | −$457M | −$190M |
| FCF margin | — | — | — | −253.7% | −19.8% |
| Share count change | 7.0% | 3.6% | 25.8% | 24.8% | 5.6% |
| Debt and strength | |||||
| Cash and short-term investments | $270M | $359M | $634M | $926M | $984M |
| Debt incl. finance leases | $0.0M | $69.7M | $115M | $118M | $340M |
| Shareholders' equity | $196M | $197M | $405M | $754M | $603M |
| Current ratio | 3.5x | 3.1x | 5.4x | 6.1x | 4.0x |
| Interest coverage | — | −74.1x | −29.9x | −33.9x | −13.5x |
| Returns and quality | |||||
| Return on equity | −110.9% | −150.1% | −124.0% | −80.3% | −42.5% |
| Return on tangible equity | −123.3% | −149.6% | −92.2% | −62.1% | −48.4% |
| Piotroski F-score | 1 | 2 | 4 | 5 | 3 |
| Altman Z'' | −6.6 | −8.4 | −3.7 | −0.7 | −1.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$81.5M
9 insiders
Of sales under plans
81%
$66.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Madrigal Pharmaceuticals, Inc. · MDGL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $440.33 a share, the company is worth $12.8B.
Source: SEC EDGAR XBRL filings (CIK 0001157601). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.